Phillip G. Febbo, MD

Phillip G. Febbo, MD, joined Veracyte in 2023 and serves as chief scientific officer and chief medical officer. Febbo is a distinguished life sciences leader with more than 25 years of experience across academia and the molecular diagnostics industry. Prior to Veracyte, he served as chief medical officer for Illumina, where he led the successful strategy to engage clinical customers. Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company’s test portfolio. Earlier in his career, Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and before that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA) and was previously a director for Varian, Inc. Febbo holds a BA in biology from Dartmouth College and an MD from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute.